Motorola a Match for Incyte Content

Incyte Genomics licensed its portfolio of proprietary gene sequences to Motorola's BioChip Systems division, which will use the information to make bioarrays for gene expression, SNP scoring, genotyping, and protein expression. In addition, Motorola software will enable users to click through to Incyte's Web site for the purchase of additional gene sequence information and reagents, a much-needed boost to Incyte's attempts to direct researchers to its Web-based genomics database.

In keeping with its open platform strategy, Incyte Genomics Inc. licensed its portfolio of proprietary gene sequences, including the LifeSeq Gold and ZooSeq databases, to Motorola Inc. 's BioChip Systems unit, which will use the information to make bioarrays used for gene expression, SNP scoring, genotyping, and protein expression. It becomes the first biochip manufacturer to take a license from Incyte, which will get royalties on array sales.

Motorola BioChip Systems, which only began beta testing its products earlier this year, is positioning itself to become a low-cost,...

Welcome to In Vivo

Create an account to read this article

More from Business Strategy

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.